SPRB SPRUCE BIOSCIENCES, INC.

Nasdaq www.sprucebiosciences.com


$ 117.00 $ 0.00 (0 %)    

Wednesday, 19-Nov-2025 08:20:33 EST
QQQ $ 597.66 $ 0.00 (0 %)
DIA $ 461.44 $ 0.00 (0 %)
SPY $ 661.00 $ 0.00 (0 %)
TLT $ 89.19 $ 0.00 (0 %)
GLD $ 378.22 $ 0.00 (0 %)
$ 115
$ 104.28
$ 110.33 x 20
$ 118.00 x 100
-- - --
$ 0.10 - $ 240.00
245,427
na
123.09M
$ 6.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 04-15-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-18-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-14-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-12-2021 03-31-2021 10-Q
20 03-22-2021 12-31-2020 10-K
21 11-18-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citizens-maintains-market-outperform-on-spruce-biosciences-raises-price-target-to-259

Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and raises the price ...

 spruce-biosciences-inc-by-spruce-biosciences-inc-q3-eps-1458-misses-1394-estimate

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(14.58) per share which missed the ...

 spruce-biosciences-may-offer-up-to-300m-in-securities

-SEC Filing

 jmp-securities-upgrades-spruce-biosciences-to-market-outperform-announces-254-price-target

JMP Securities analyst Jonathan Wolleben upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Market Outperform ...

 kenneth-griffin-reports-999-passive-stake-in-spruce-biosciences-inc-as-of-oct-9

-SEC Filing

 reported-earlier-spruce-biosciences-reveals-500m-private-placement-financing

Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

 spruce-biosciences-sprb-stock-jumps-30-after-hours-following-red-hot-rally-on-monday-heres-why

Spruce Biosciences shares soared after the FDA granted Breakthrough Therapy Designation to its lead treatment for Sanfilippo Sy...

 spruce-biosciences-stock-is-soaring-today-heres-why

Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory u...

 spruce-biosciences-says-fda-grants-breakthrough-therapy-designation-to-tralesinidase-alfa-enzyme-replacement-therapy-for-treatment-of-sanfilippo-syndrome-type-b

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION